Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA's decision on its KRAS inhibitor adagrasib in non-small cell lung cancer (NSCLC).

Mirati Therapeutics’ hopes of an EU approval for its KRAS inhibitor Krazati in the EU have been thrown into disarray after the EMA’s human medicines committee rejected the drug as a lung ...

After hours: February 7 at 4:02:41 PM EST Loading Chart for EWTX ...

After hours: February 13 at 4:09:41 PM EST Loading Chart for ACHL ...

Dyne Therapeutics Inc.-5.60% $1.56B ...

Sanofi S.A. Part Cert 0.02% €8.03M ...